NTRK1 and cancer: The clinical trial data used in this indirect treatment comparison suggest that the mechanism of NTRK inhibition is efficacious and safe in treating solid cancers with TRK fusion-positive cancer, and the present indirect treatment comparison showed that larotrectinib had a favorable efficacy and comparable safety profile compared to entrectinib after adjusting for the heterogeneity in patient characteristics between the trial populations.